Appendix Table.

Adjusted Difference-in-Difference in Rates of Stopping Therapy and Resuming Therapy in Response to Coverage Gap

	Statins	Anti- Hypertensive, combo	Oral Hypoglycemic	Calcium channel blockers	Anti- hypertensives, other	ACE/ARB	Beta Blockers	Diuretics	Digitalis glycosides
Stop
Non-LIS, Gap coverage vs. LIS	3.8%	2.0%	1.6%	−1.5%	−2.3%	−0.9%	−0.9%	−1.0%	−0.5%
Non-LIS, No gap coverage vs. LIS	4.5%	1.7%	2.7%	−0.1%	−0.9%	−0.2%	0.4%	0.5%	0.1%
Resume
Non-LIS, Gap coverage vs. LIS	8.0%	4.6%	5.4%	−0.4%	−3.5%	5.6%	4.4%	1.9%	1.0%
Non-LIS, No gap coverage vs. LIS	8.8%	6.9%	7.9%	3.7%	−1.5%	5.8%	4.9%	0.7%	3.7%
Number of observations	245,482	76,586	195,949	122,675	27,835	207,418	153,582	117,598	29,731

NOTE: Sample is individuals with diabetes and ages 65 that reach coverage gap in 2007. Individuals had to stay in coverage gap for at least 40 days. Resumption is defined as stopping a drug in the coverage gap in 2007 and resuming in the first quarter of 2008. Years: 2007, 2008